Automated Author ProfileChen, Jia-Yu
Chen, Jia-Yu
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 5.5 (sum of 10 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
A comprehensive investigation delineating the prevalence of sarcopenia across different infection phases, from acute COVID-19 to long COVID, is lacking. Meanwhile, the relationship between sarcopenia and adverse outcomes among COVID-19 patients remains inconsistent. A systematic search of MEDLINE/PubMed, Embase, Cochrane Library, Web of Science, and Scopus, before 22nd February 2025, was conducted to identify studies assessing sarcopenia prevalence in acute COVID-19 and long COVID. Random effects meta-analyses were performed to estimate the pooled prevalence of sarcopenia for acute COVID-19 and long COVID patients. Subgroup analyses stratified by assessment tool, region, income, hospitalization status, and age were performed. The associations between sarcopenia and COVID-19-related clinical outcomes were further quantified. A total of 39 studies with 6,982 individuals were included. The pooled prevalence of sarcopenia was 48.7% (95% confidence interval (CI): 39.6–57.9%) in acute COVID-19 and 23.5% (95% CI: 12.7–39.4%) in long COVID. In acute COVID-19 patients, sarcopenia was not significantly associated with length of stay (mean difference = 2.215, 95% CI: −0.004 to 4.433), mechanical ventilation (Odds ratio (OR) = 1.80, 95% CI: 0.84–3.85), admission to the intensive care unit (OR = 1.05, 95% CI: 0.63–1.77), or mortality (OR = 1.41, 95% CI: 0.86–2.32), but was significantly associated with tracheostomy (OR = 2.48, 95% CI: 1.28–4.82). In conclusion, our findings indicate that sarcopenia is highly prevalent in acute COVID-19 and persists in a substantial proportion of long COVID patients, suggesting prolonged muscle loss beyond the acute phase. Future well-designed studies are needed to further investigate the association between sarcopenia and short-term and long-term prognostic outcomes in both acute and long COVID patients.
Authors
- Xu, Ying ;
- Xu, Jia-Wen ;
- Wu, You ;
- Rong, Li-Juan ;
- Ye, Li ;
- Franco, Oscar H. ;
- Chien, Ching-Wen ;
- Feng, Xiao-Ru ;
- Chen, Jia-Yu ;
- Tung, Tao-Hsin
A comprehensive investigation delineating the prevalence of sarcopenia across different infection phases, from acute COVID-19 to long COVID, is lacking. Meanwhile, the relationship between sarcopenia and adverse outcomes among COVID-19 patients remains inconsistent. A systematic search of MEDLINE/PubMed, Embase, Cochrane Library, Web of Science, and Scopus, before 22nd February 2025, was conducted to identify studies assessing sarcopenia prevalence in acute COVID-19 and long COVID. Random effects meta-analyses were performed to estimate the pooled prevalence of sarcopenia for acute COVID-19 and long COVID patients. Subgroup analyses stratified by assessment tool, region, income, hospitalization status, and age were performed. The associations between sarcopenia and COVID-19-related clinical outcomes were further quantified. A total of 39 studies with 6,982 individuals were included. The pooled prevalence of sarcopenia was 48.7% (95% confidence interval (CI): 39.6–57.9%) in acute COVID-19 and 23.5% (95% CI: 12.7–39.4%) in long COVID. In acute COVID-19 patients, sarcopenia was not significantly associated with length of stay (mean difference = 2.215, 95% CI: −0.004 to 4.433), mechanical ventilation (Odds ratio (OR) = 1.80, 95% CI: 0.84–3.85), admission to the intensive care unit (OR = 1.05, 95% CI: 0.63–1.77), or mortality (OR = 1.41, 95% CI: 0.86–2.32), but was significantly associated with tracheostomy (OR = 2.48, 95% CI: 1.28–4.82). In conclusion, our findings indicate that sarcopenia is highly prevalent in acute COVID-19 and persists in a substantial proportion of long COVID patients, suggesting prolonged muscle loss beyond the acute phase. Future well-designed studies are needed to further investigate the association between sarcopenia and short-term and long-term prognostic outcomes in both acute and long COVID patients.
Authors
- Xu, Ying ;
- Xu, Jia-Wen ;
- Wu, You ;
- Rong, Li-Juan ;
- Ye, Li ;
- Franco, Oscar H. ;
- Chien, Ching-Wen ;
- Feng, Xiao-Ru ;
- Chen, Jia-Yu ;
- Tung, Tao-Hsin
Table S1. Statistics of the deep sequencing data used in this study. (XLSX 12 kb)
Authors
- An, Ni ;
- Ding, Wanqiu ;
- Yang, Xin-Zhuang ;
- Peng, Jiguang ;
- He, Bin ;
- Shen, Qing ;
- Lu, Fujian ;
- He, Aibin ;
- Zhang, Yong ;
- Tan, Bertrand ;
- Chen, Jia-Yu ;
- Li, Chuan-Yun
Table S3. A-to-I editing events located on polymorphic sites in the macaque population. (XLSX 1879 kb)
Authors
- An, Ni ;
- Ding, Wanqiu ;
- Yang, Xin-Zhuang ;
- Peng, Jiguang ;
- He, Bin ;
- Shen, Qing ;
- Lu, Fujian ;
- He, Aibin ;
- Zhang, Yong ;
- Tan, Bertrand ;
- Chen, Jia-Yu ;
- Li, Chuan-Yun
Table S4. 54 randomly selected polyAG sites of targeted DNA sequencing. (XLSX 13 kb)
Authors
- An, Ni ;
- Ding, Wanqiu ;
- Yang, Xin-Zhuang ;
- Peng, Jiguang ;
- He, Bin ;
- Shen, Qing ;
- Lu, Fujian ;
- He, Aibin ;
- Zhang, Yong ;
- Tan, Bertrand ;
- Chen, Jia-Yu ;
- Li, Chuan-Yun
Table S4. 54 randomly selected polyAG sites of targeted DNA sequencing. (XLSX 13 kb)
Authors
- An, Ni ;
- Ding, Wanqiu ;
- Yang, Xin-Zhuang ;
- Peng, Jiguang ;
- He, Bin ;
- Shen, Qing ;
- Lu, Fujian ;
- He, Aibin ;
- Zhang, Yong ;
- Tan, Bertrand ;
- Chen, Jia-Yu ;
- Li, Chuan-Yun
Table S3. A-to-I editing events located on polymorphic sites in the macaque population. (XLSX 1879 kb)
Authors
- An, Ni ;
- Ding, Wanqiu ;
- Yang, Xin-Zhuang ;
- Peng, Jiguang ;
- He, Bin ;
- Shen, Qing ;
- Lu, Fujian ;
- He, Aibin ;
- Zhang, Yong ;
- Tan, Bertrand ;
- Chen, Jia-Yu ;
- Li, Chuan-Yun
Table S1. Statistics of the deep sequencing data used in this study. (XLSX 12 kb)
Authors
- Tan, Bertrand ;
- Chen, Jia-Yu ;
- Li, Chuan-Yun ;
- An, Ni ;
- Ding, Wanqiu ;
- Yang, Xin-Zhuang ;
- Peng, Jiguang ;
- He, Bin ;
- Shen, Qing ;
- Lu, Fujian ;
- He, Aibin ;
- Zhang, Yong
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
Authors
- Chen, Jia-Yu ;
- Huang, Chiung-Yao ;
- Lin, Yun-Sheng ;
- Hwang, Tsong-Long ;
- Wang, Wei-Lung ;
- Chiou, Shu-Fen ;
- Sheu, Jyh-Horng
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
Authors
- Liu, Wei-Sheng ;
- Wu, Da-Xiang ;
- Chen, Jia-Yu ;
- Wang, Hui-Juan ;
- Tang, Xiao-Liang